Are Payers Ready To Address The Financial Challenges Associated With Gene Therapy?

Are Payers Ready To Address The Financial Challenges Associated With Gene Therapy?

• Michael Ciarametaro
 
• Genia Long
 
• Michaela Johnson
 
• Noam Kirson
 
• Robert Dubois

JUNE 28, 201810.1377/hblog20180626.330036

•  TOOLS
•  SHARE

The development of transformative therapies such as gene therapy has triggered a public discussion about the market access challenges such therapies will face, the viability of alternative financing mechanisms to address those challenges, and the net results for patient access. While gene therapies hold the promise of substantial benefits, some patients will face barriers accessing them due to the nature of the clinical intervention, the characteristics of the US insurance system, and the interaction between the two.